Development of a nursing practice scale for rheumatoid arthritis treatment with biological disease-modifying anti-rheumatic drugs

被引:1
|
作者
Song, Fang [1 ,3 ]
Nakatani, Hisae [1 ]
Sugiyama, Eiji [2 ]
Hirata, Shintaro [2 ]
机构
[1] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan
[2] Hiroshima Univ Hosp, Dept Clin Immunol & Rheumatol, Hiroshima, Japan
[3] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, 1 2 3, Kasumi, Minami ku, Hiroshima 7348553, Japan
关键词
Biological disease-modifying anti-rheumatic drugs; Certified Nurses by Japan Rheumatism Foundation; nursing practice scale; rheumatoid arthritis; registered nurses; CARE;
D O I
10.1093/mr/road064
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The objective of the study was to develop a nursing practice scale for rheumatoid arthritis treatment with biological disease-modifying anti-rheumatic drugs. Methods An anonymous self-administered questionnaire survey was administered to 1826 nurses, 960 of whom were Certified Nurses by Japan Rheumatism Foundation (CNJRFs) and 866 were registered nurses (RNs). Using exploratory factor analysis, criterion validity, and known-groups technique, we assessed the reliability and validity of the self-created 19-item nursing practice scale to evaluate the care provided to patients with rheumatoid arthritis receiving biological disease-modifying anti-rheumatic drugs based on the nurse's role as clarified from a literature review of relevant studies. Results A total of 698 (38.4%) responses were collected from 407 CNJRFs and 291 RNs. Exploratory factor analysis was conducted on 18 items to examine three factors: 'nursing to enhance patients' capacity for self-care', 'nursing in which patients participate in decision-making', and 'nursing in which team medical care is promoted'. Cronbach's & alpha; was .95. The Spearman's coefficient was & rho; = .738 for criterion validity. Using the known-groups technique, CNJRFs had higher total scale scores than RNs (P < .05). Conclusions The results confirmed the reliability, criterion validity, and construct validity of the scale.
引用
收藏
页码:479 / 487
页数:9
相关论文
共 50 条
  • [2] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [3] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [4] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [5] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [6] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    [J]. Clinical Rheumatology, 2020, 39 : 207 - 216
  • [7] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
    Pombo-Suarez, Manuel
    Gomez-Reino, Juan
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 148
  • [8] ANA DEVELOPMENT IS ASSOCIATED WITH POOR RESPONSE TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Ishikawa, Y.
    Hashimoto, M.
    Ito, H.
    Tanaka, M.
    Yukawa, N.
    Fujii, T.
    Mimori, T.
    Terao, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 107 - 108
  • [9] Use of Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis in Quebec, Canada
    Roussy, Jean-Pascal
    Bessette, Louis
    Bernatsky, Sasha
    Rahme, Elham
    Legare, Jean
    Lachaine, Jean
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S855 - S855
  • [10] USE OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS IN QUEBEC, CANADA
    Roussy, J. P.
    Bessette, L.
    Bernatsky, S.
    Rahme, E.
    Legare, J.
    Lachaine, J.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A316 - A316